Detalles de la búsqueda
1.
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes.
Diabetes Obes Metab
; 23(2): 425-433, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33084149
2.
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.
Diabetes Obes Metab
; 23(8): 1886-1891, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33950573
3.
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.
Diabetes Obes Metab
; 23(12): 2775-2784, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34463409
4.
Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
Diabetes Obes Metab
; 23(5): 1173-1181, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33502090
5.
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.
Eur Heart J
; 41(2): 209-217, 2020 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31504427
6.
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Circulation
; 139(11): 1384-1395, 2019 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30586757
7.
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
Circulation
; 139(3): 351-361, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30586723
8.
Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome.
Hum Reprod
; 35(6): 1421-1431, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32510130
9.
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.
Diabetes Obes Metab
; 22(12): 2335-2347, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32744354
10.
Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Diabetes Obes Metab
; 22(4): 631-639, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31789445
11.
Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME.
Diabetes Obes Metab
; 22(7): 1207-1214, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32030863
12.
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Diabetes Obes Metab
; 22(7): 1151-1156, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32115840
13.
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Diabetes Obes Metab
; 22(7): 1141-1150, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32227432
14.
Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
Diabetes Obes Metab
; 22(3): 427-433, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31858718
15.
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
Diabetes Obes Metab
; 21(5): 1073-1078, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30690856
16.
Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
Age Ageing
; 48(6): 859-866, 2019 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31579904
17.
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Eur Heart J
; 39(5): 363-370, 2018 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29020355
18.
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
JAMA
; 322(12): 1155-1166, 2019 Sep 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31536101
19.
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
JAMA
; 321(1): 69-79, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30418475
20.
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.
Diabetologia
; 61(10): 2155-2163, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30066148